Summary: final paper of a pre-print that appeared April 29, 2021 - showing both Vitamin D3 and the more direct form (Calcifediol) were both protective. Taken 15 days prior to hospital admission was more protective than 30 days prior (time factor) - and Calcifediol was more effective than Vitamin D3 (not surprising the time it takes for Vitamin D3 supplemention to impact levels in blood.

Why isn't Vitamin D3 standard of care/prophylaxis for all at-risk folks - nursing homes etc. ?

 

Figure 2:

https://imgur.com/a/SDeRFOh

NOTE: ADM in graph is composite measure.

Paper:

https://www.nature.com/articles/s41598-021-02701-5

Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients

Carlos Loucera, 

María Peña-Chilet, 

Marina Esteban-Medina, 

Dolores Muñoyerro-Muñiz, 

Román Villegas, 

Jose Lopez-Miranda, 

Jesus Rodriguez-Baño, 

Isaac Túnez, 

Roger Bouillon, 

Joaquin Dopazo & 

Jose Manuel Quesada Gomez 

03 December 2021

 

Abstract

COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. We present a survival study on a retrospective cohort of 15,968 patients, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020. Based on a central registry of electronic health records (the Andalusian Population Health Database, BPS), prescription of vitamin D or its metabolites within 15–30 days before hospitalization were recorded. The effect of prescription of vitamin D (metabolites) for other indication previous to the hospitalization was studied with respect to patient survival. Kaplan–Meier survival curves and hazard ratios support an association between prescription of these metabolites and patient survival. Such association was stronger for calcifediol (Hazard Ratio, HR = 0.67, with 95% confidence interval, CI, of [0.50–0.91]) than for cholecalciferol (HR = 0.75, with 95% CI of [0.61–0.91]), when prescribed 15 days prior hospitalization. Although the relation is maintained, there is a general decrease of this effect when a longer period of 30 days prior hospitalization is considered (calcifediol HR = 0.73, with 95% CI [0.57–0.95] and cholecalciferol HR = 0.88, with 95% CI [0.75, 1.03]), suggesting that association was stronger when the prescription was closer to the hospitalization.

 

pre-print:

https://www.medrxiv.org/content/10.1101/2021.04.27.21255937v1 Real world evidence of calcifediol use and mortality rate of COVID-19 hospitalized in a large cohort of 16,401 Andalusian patients

Carlos Loucera, María Peña-Chilet, Marina Esteban-Medina, Dolores Muñoyerro-Muñiz, Román Villegas, Jose Lopez-Miranda, Jesus Rodriguez-Baño, Isaac Túnez, Roger Bouillon, Joaquin Dopazo, Jose Manuel Quesada Gomez

doi: https://doi.org/10.1101/2021.04.27.21255937

April 29, 2021